We're back with today's Opening Belle!
Click here to listen on Spotify!
What do we cover?
🚚 Remoaners crying as Brexit trade recovers
🏃♂️ How do we grow with fewer people even wanting to work?
📈 Fitting the narrative to the chart
💭 Why overcomplicate?
Hot & not 🔥🚫
🔥 Diffusion Pharmaceuticals are up a whopping 29% after completing an early stage study of a COVID treatment known very commonly as...
Trans sodium crocetinate.
Never heard of it, but sounds great.
This is to treat hypoxia in hospitalised patients.
🚫 BlueBird Biotech has taken an absolute whack after the company suspends trials of sickle cell disease treatment.
The firm said it is temporarily suspending Phase 1/2 and Phase 3 trials of its LentiGlobin gene therapy for sickle cell disease after a report of a suspected unexpected serious adverse reaction of acute myeloid leukaemia.
The patient involved was treated more than five years ago and has not been diagnosed with AML, the company said in a statement...
Lesson to be learnt: biotech is an absolute mental sector, and small shocks like this can seriously affect a share price adversely. Liquidity matters!
A DeFi hot take...
We spoke about being short convexity last week and that many crypto startups are subject to this problem...
Here's a recap of an article focused on this...
Being a traditional exchange, EQUOS our partner, is not subject to this problem...
EQUOS is a digital asset exchange built to institutional standards & available to everyone.
They've created a truly institutional-grade infrastructure while enabling anybody to join. Users can enjoy a higher level of security, capital efficiency and reliability.
Founded on real-world values of fairness and equality to promote liquidity and help build long-term equity.
With a focus on innovation, transparency, and trust, EQUOS is a part of Diginex, the first Nasdaq-listed company with a cryptocurrency exchange.
Do check 'em out.
Marcus for the Masses
Goldman have jumped onto the retail investing boom by launching their first retail robo-adviser via their Marcus product.
Personally, I'm not sure on how well it'll be taken up, since many seem to want to take their investing into their own hands, but we'll see.
The funny things is this...
Across demographic groups, use of robo-advisors is highest among consumers with at least $500,000 in investable assets, according to a survey of more than 5,400 households by data and analytics firm Hearts & Wallets.
Nearly half of consumers using an automated portfolio consider themselves either “experienced” or “very experienced” at investing, and 57% of these investors also use financial professionals.
Share this article: